Lecanemab has been heralded as good news for a medical system that is rapidly breaking down, Alzheimer's disease at epidemic levels, and the NHS now in terminal decline?
Headlines in all the mainstream national media yesterday (30th November 2022) certainly suggests that it is. The Alzheimer's Society has described Lecanemab as "momentous".
Yet is it really "good news"? Let's look more closely into what we are being told.